Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate.
TLDR
Patients treated with a 5.0‐mg daily dose of diethylstilbestrol (DES) had an increased incidence of fatal and non‐fatal cardiovascular disease when compared to placebo in all stages of prostatic cancer (p < 0.025).Abstract:
Patients treated with a 5.0-mg daily dose of diethylstilbestrol (DES) had an increased incidence of fatal and non-fatal cardiovascular disease when compared to placebo in all stages of prostatic cancer (p < 0.025). The pretreatment cardiovascular status of estrogen-treated patients was generally better than those treated with placebo. Therapy with DES 5.0 mg did not increase survival of Stage III or IV patients significantly when compared to placebo. The decrease in cancer mortality associated with the 5.0-mg dose of DES was offset by an increase in deaths from cardiovascular causes. Early endocrine treatment of patients with asymptomatic Stage III carcinoma is not indicated. Endocrine therapy should be started early only in Stage IV patients. When DES is preferred, it should be administered in a dose lower than 5.0 mg. Complications of estrogen therapy may be due to an increased incidence of thromboembolism.read more
Citations
More filters
Journal ArticleDOI
Histologic grading of prostate cancer: A perspective
TL;DR: The predictive success of grading suggests that prostate cancers have more or less fixed degrees of malignancy and growth rates (a hypothesis of "biologic determinism") rather than a steady increase inmalignancy with time.
Journal ArticleDOI
The veterans administration cooperative urological research group's studies of cancer of the prostate
TL;DR: The overall recommendation at present is that patients with prostatic cancer should not be treated until their symptoms require relief, and at that time it is recommended starting treatment with 1.0 mg DES daily.
Journal ArticleDOI
The hypercoagulable states.
TL;DR: The complex pathophysiologic features of these secondary hypercoagulable states are discussed, and a framework is provided for the laboratory investigation and systematic clinical approach to the patient.
Journal ArticleDOI
Why do women live longer than men
TL;DR: Suggestions for reducing male mortality are made by changing the social conditions which foster in men the behaviors that elevate their mortality, including using guns, being adventurous and acting unafraid, working at hazardous jobs and drinking alcohol.
Journal ArticleDOI
Sex, plasma lipoproteins, and atherosclerosis: Prevailing assumptions and outstanding questions
TL;DR: The hypothesis that the incidence of coronary heart disease (CHD) is higher in men than in women due to differences in plasma lipoprotein risk factors between the sexes is reviewed and evidence relating these sex differences in CHD and lipoproteins to the effects of sex hormones is critically examined.
References
More filters
Journal ArticleDOI
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
TL;DR: Gutman et al. as mentioned in this paper showed that the acid phosphatase of serum is reduced in metastatic carcinoma of the prostate by decreasing the activity of androgens through castration or estrogenic injections and that this enzyme is increased by injecting androgens.
Journal Article
Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
TL;DR: It is demonstrated that a marked rise in acid phosphatase in serum is associated with the appearance or spread of roentgenologically demonstrable skeletal metastases and implies dissemination of the primary tumor and thus is of unfavorable prognostic significance.
Journal ArticleDOI
Carcinoma of the Prostate: Treatment Comparisons
Lino J. Arduino,John C. Bailar,Leslie E. Becker,Henry I. Berman,Arthur J. Bischoff,Richard P. Doe,James S. Elliot,Earl Haltiwanger,Robert B. Higgins,Asher O. Hoodin,Joseph Jorgens,Howard C. Kramer,Lyndon E. Lee,Maxwell Malament,George T. Mellinger,Fathollah K. Mostofi,William L. Parry,Lloyd S. Rogers,A. Hardy Ulm,Mark W. Wolcott +19 more
Journal ArticleDOI
Elevation of certain plasma proteins in man following estrogen administration: a dose-response relationship.
TL;DR: The degree of elevation of the plasma concentrations of corticosteroid-binding globulin (CBG), β-glucuronidase and ceruloplasmin in response to estrogen administration was shown to be related, within limits, to the dose of estrogen.
Journal ArticleDOI
Serum protein alterations produced in women by synthetic estrogens.
TL;DR: No appreciable difference in the effects of the estrogen alone or combined with the progestational agent was found except perhaps in the case of the “pregnancy” protein, although ceruloplasmin, CBG, TBG and G-c components were consistently elevated by estrogen treatment.
Related Papers (5)
Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo
John C. Bailar,David P. Byar +1 more